Monopar Pharma (MNPR): Price-to-Revenue Ratio

Brandmark of Monopar Corp (MNPR)

Monopar Therapeutics operates on an asset-light model, outsourcing drug production to third-party contractors. This chart on the GURU.Markets platform illustrates the P/S multiple trend, where represents the current value of the metric. Robotic systems accelerate molecule discovery here, while resilience to economic cycles ensures constant demand for oncology therapy, independent of market conditions.

MNPR Monopar Therapeutics P/S Multiple (07/04/2022 - 11/13/2026)

Monopar Pharma (MNPR) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price monopartx.com|MNPR - Price Target Chart
- stock exchange capitalization data:
Market Value Monopar Pharma|MNPR - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Monopar Therapeutics|MNPR - Book Capitalization|Market Value to Equity Ratio monopartx.com|MNPR - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Monopar Therapeutics|MNPR - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Monopar Corp|MNPR - Company Total Debt|Debt to Book Capital Monopar Pharma|MNPR - Company Long-Term Debts|Company Short-Term Loans and Borrowings Monopar Therapeutics|Immediate Liquidity monopartx.com
- earnings and multiples data:
MNPR - Company Net Income|Expected Net Income Monopar Therapeutics|MNPR - P/E Multiple|Forward P/E Multiple Monopar Therapeutics Inc|MNPR - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Monopar Pharma|MNPR - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Monopar Therapeutics|MNPR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months monopartx.com|MNPR - Earnings per share growth in current year|Expected net earnings per share growth next year Monopar Therapeutics
- issuer revenue and sales details:
MNPR - Company Revenue|Company Revenue Forecast monopartx.com|MNPR - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Monopar Pharma
Summary company analytics:monopartx.com
Mass-produced product of Monopar Corp

To identify stability drivers, the investor analyzes the market capitalization to annual revenue ratio, where the current revenue multiple stands at . This metric assesses the market value of every dollar of sales, which is critical for Monopar Therapeutics (MNPR), as its value is based on the development of targeted radiopharmaceuticals and innovative antibodies for precision oncology.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Inhibrx Corp|IMAB: P/S Multiple|Price-to-Revenue Multiple fennecpharma.com FENC|Market Cap to Revenue HRTX|Price to Sales Nuvectis Pharma Inc. NVCT|Market Cap to Revenue CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Market Capitalization-to-Revenue Ratio|Cardiff Oncology - Market Cap to Revenue|Market Cap to Sales Volume BYSI (beyondspringpharma.com)|BioAtla Corp - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: P/S Multiple|Price to Sales Cellectar Corp (CLRB)|Price-to-Revenue Ratio BioLineRx Ltd.|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|g1therapeutics.com (GTHX) - Price-to-Revenue Ratio|Market Cap to Revenue Kronos Bio Inc|Price-to-Revenue Ratio Kintara|Price to Sales Oncternal Corp ONCT|Price-to-Revenue Ratio Portage Biotech Inc. (PRTG)